Concomitant andexanet alfa and 4 F-PCC for Factor Xa inhibitor associated intracranial hemorrhage.

Autor: Orban JE 3rd; Lexington Medical Center, 2720 Sunset Blvd, West Columbia, SC, 29169, USA. Electronic address: jeorban@lexhealth.org., Ruckel C; Baptist Memorial Hospital, Memphis, USA., Harlan S; Baptist Memorial Hospital, Memphis, USA.
Jazyk: angličtina
Zdroj: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2023 Oct; Vol. 233, pp. 107908. Date of Electronic Publication: 2023 Jul 20.
DOI: 10.1016/j.clineuro.2023.107908
Abstrakt: Andexanet alfa is the only FDA approved drug for acute reversal of life-threatening bleeding associated with oral factor Xa inhibitor agents. The case series investigates clinical outcomes of four patients receiving concomitant Andexanet alfa and Four Factor Prothrombin Concentrate Complex (4 F-PCC) for acute reversal of intracranial hemorrhage. Following administration, effective hemostasis was achieved in two patients (50%) and one patient (25%) experienced an acute ischemic stroke. Two patients (50%) expired prior to discharge without achieving hemostasis. This case series serves to further expand the limited data on the concomitant administration of Andexanet alfa and 4 F-PCC.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: